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From its ﬁrst description by Thomas Hodgkin in 1832, Hodgkin’s disease, now called Hodgkin’s lymphoma, has continued
to be a fascinating neoplasm even to this day. In this review, historical aspects, epidemiology, diagnosis, tumor biology, new
observations related to host-microenvironment interactions, gene copy number variation, and gene expression proﬁling in this
complex neoplasm are described, with an exploration of chemoresistance mechanisms and potential novel therapies for refractory
disease.
1. HistoricalAspects
In this section a brief overview of the history of the
discovery and histologic deﬁnition of Hodgkin’s lymphoma
is presented, highlighting some new observations that shed
light on the earlier ﬁndings in patients with this disease.
Hodgkin presented seven autopsy cases in his now fa-
mous paper “On some morbid appearances of the absorbent
glands and spleen” to the Royal Medical and Chirurgical
Society of London on January 10 and 24, 1832, the text of
which was published in the Transactions of the Medical
and Chirurgical Society of London [1]. The full text of
his paper has been digitized by Google and is available at
http://books.google.ca/ and also at http://www.ncbi.nlm.nih
.gov/pmc/articles/PMC2116706/. Although Hodgkin was
aware of light microscopy and had used microscopy in an
earlier published study with Lister [2], he did not actually
examine these cases under the microscope. In 1998, Poston
proved by histology and immunohistochemistry that cases
II and VI (only cases II, IV, and VI have ﬁxed tissue archived
since 1832) indeed represent what we now recognize as
Hodgkin’s lymphoma (HL) whereas case IV was a case of
non-Hodgkin’s lymphoma (NHL), possibly a peripheral T
cell lymphoma (PTCL) with rare CD15+ Reed-Sternberg-
like cells [3]. It is therefore apparent that Thomas Hodgkin
had described both forms of lymphoma, and in his paper
PostonarguesthatalllymphomasshouldbecalledHodgkin’s
lymphoma, subdivided into Reed Sternberg and Non-Reed
Sternberg types [3]. The seventh case described by Hodgkin
duringhispresentationwasonewhoseautopsyﬁndingswere
recorded by Robert Carswell in 1828, elegantly illustrated
in watercolor paintings which have been reproduced in
Dawson’s article “The original illustrations of Hodgkin’s
disease” [4]. Arguably, Carswell was the ﬁrst to describe
the entity in detail, although Hodgkin makes reference to
Malpighi’s description of similar lesions in 1666, brought to
his attention by a friend, Heming [1].
The ﬁrst histologic classiﬁcation of HD was described
by Jackson and Parker in 1944 [5]. They divided HD into 3
types, paragranuloma, granuloma, and sarcoma, which are
equivalent to nodular lymphocyte predominant, nodular
sclerosis, and lymphocyte depleted types, respectively, as
recognized in the current classiﬁcation system (see the fol-
lowing). Modern terminology related to the histopathology2 Advances in Hematology
of HD was coined in 1966 by Lukes and Butler, who
introduced 6 types, including (1) lymphocytic and/or
histiocytic (L & H) nodular, (2) L & H diﬀuse, (3) nodular
sclerosis, (4) mixed, (5) diﬀuse ﬁbrosis, and (6) reticular
[6]. In their paper, they reviewed extensively the previous
literature on HD and the various terms used by diﬀerent
authors and provide detailed descriptions of Reed-Sternberg
cells and their variants. They described the cellular variant
of nodular sclerosis and the birefringent bands of collagen
in the usual form of NS and proposed that the various
histologic types except for NS represent an evolution from
L&Hn o d u l a rt oL&Hd i ﬀuse to mixed, diﬀuse ﬁbrosis, or
reticularformsthroughalossoflymphocytes.Theycorrectly
interpreted the presence of lymphocytes as evidence of a
host response rather than an HD being a mixed lymphoma
of small and large cells [6]. This was later reduced to 4
types—lymphocyte predominance (LP), nodular sclerosis
(NS), mixed cellularity (MC), and lymphocyte depletion
(LD) [7].
Current classiﬁcation systems have replaced the term
Hodgkin’s disease (HD) with Hodgkin’s lymphoma (HL),
diﬀerentiated between lymphocyte predominant and classi-
cal HL, and introduced the subtype lymphocyte rich (LR)
classical HL [8, 9].
2. GlobalIncidence, MortalityRates,
andEpidemiology
In this section the patterns of variation in incidence and
mortality rates across countries that track and manage HL
are discussed.
HL comprises 11% of all lymphomas in the Western
world. The estimated incidence of all types of lymphoma in
2010 for Canada was 8,430, of which 7,500 cases are expected
to be non-Hodgkin’s lymphomas (NHL) and 930 HL [10].
In the United States of America, the estimate for 2009 was
74,490 total lymphomas, including 65,980 NHL, and 8,510
HL [11].
HL had a worldwide incidence of 67,887 cases in 2008,
with an age-standardized rate per 100,000 (both genders) of
1.0 [12]. Compared with North America, which has an age-
standardized rate (ASR) for HL of 3.2 per 100,000 in whites,
HL is relatively rare in Japan (ASR of 0.3 per 100,000 males)
and China (ASR of 0.2 per 100,000 males). In developing
countries, the incidence of HL is variable and can be higher
than in developed countries; for example, the ASR for HL in
Yemen is 5.7 per 100,000 males [13].
Considerable regional variation may be seen in several
countries. For instance, the highest recorded ASR in the
world is in Biella, Italy, at 6.9 per 100,000 males, whereas in
Sondrio, Italy, the HL ASR is 1.6 per 100,000 males. Even in
low HL ASR countries such as China, regional variation in
ASR exists, ranging from a low of 0.1 in Harbin to a high of
0.9 per 100,000 males in Hong Kong [13].
Age-standardized mortality rates are the highest in the
Middle East at 1.2 per 100,000 (both genders included) and
the lowest in the Western Paciﬁc region at 0.2 per 100,000
(Table 1). The mortality to incidence ratio, a measure of
diseaseseverityoreﬀectivenessoftherapy,ishighestinAfrica
at 0.9 and lowest in the Americas at 0.2 (Table 1).
In developed countries HL is relatively rare in children
below the age of 5 years but is the commonest type of cancer
in adolescents. It shows a bimodal age distribution with a
second peak in patients over the age of 59 years. U.S. Black
males seem to show a trimodal age distribution (Figure 1).
The ASR by histological type shows considerable global
and regional variation. For instance, the highest ASR for
NLPHL is in the Northwest Territories, Canada, at 0.9 per
100,000 males, for LR in Biella Province, Italy, at 0.8 per
100,000 males, for NS also in Biella, Italy at 4.2 per 100,000
males, for MC in Milan, Italy, at 1.4 per 100,000 males, and
for LD in Kyadondo County, Uganda, at 0.4 per 100,000
males [13].
The age distribution of histologic subtypes in developed
c o u n t r i e si sa l s on o t a b l e( r e v i e w e di n[ 14]). Childhood cases
(deﬁnedas ≤14y earso fage)o fHLt e ndt obep r ed o minantl y
in males, with MC HL in up to 45% of cases and NLPHL in
up to 20% of cases, while in adolescents and young adults
(15–35 years of age) and adults (>35 years of age), no gender
bias is seen, and the majority of cases (up to 80%) are of the
NS histologic subtype. In adults older than 55 years of age,
u pt o5 0 %a r eo fM Ct y p e[ 14].
The standard histologic and immunohistochemical fea-
t u r e so fH Lh a v er e c e n t l yb e e nr e v i e w e di nd e t a i la n d
illustrated by Eberle et al. [15] and thus not discussed in this
paper. It should be noted, however, that there is considerable
interobserver variation amongst pathologists regarding the
diagnosis and subclassiﬁcation of Hodgkin’s lymphoma, and
in the absence of central review by expert pathologists, some
of these global statistics may be misleading (see section on
interobserver variability). This is further complicated by the
fact that there are cases that are not easily classiﬁed as they
have overlapping features of HL and NHL, so called grey-




tion in the early literature due to the recent developments in
the incidence and successful control of HIV+ disease in the
Western world. These are discussed in this section. Some of
the classic symptoms of alcohol-induced pain may now have
a biological explanation.
A comprehensive discussion of the clinical presentation
and natural history of HL has been published by Connors
[17]. For the purpose of this review, only the key points
are summarized. The clinical presentation of HL depends
on the geographic region, age of the patient, and diseases
aﬀectingtheimmunestatusofthepatient.Thusindeveloped
countries, HL presents in adolescents and young adults as
localized, persistent, painless, ﬁrm lymphadenopathy, most
commonly in cervical nodes, supraclavicular nodes, and less
commonly in axillary nodes [17].
In developing countries, advanced stage and lack of
a bimodal age pattern may be seen more often than in
developed countries in addition to histologic diﬀerencesAdvances in Hematology 3
Table 1: Age-standardized incidence and mortality rates ranked by mortality to incidence ratio (case fatality ratio). Calculations are based
on data from GLOBOCAN 2008 [12].
Region Numbers per year Incidence ASR Deaths per year Mortality ASR Mortality to incidence ratio
WHO Africa region 5879 0.9 4893 0.8 0.9
WHO East Mediterranean region 7663 1.4 6004 1.2 0.9
Less developed regions 40137 0.7 23698 0.5 0.7
WHO South-East Asia region 11682 0.7 6276 0.4 0.6
WHO Western Paciﬁc region 8476 0.4 3478 0.2 0.5
World 67887 1 30205 0.4 0.4
WHO Europe region 19342 2 5898 0.5 0.3
More developed regions 27750 2 6507 0.4 0.2
































































































































Figure 1: Age-speciﬁc rates of incidence (based on data from SEER
Cancer Statistics Review) [16].
such as a high prevalence of mixed cellularity (MC) HL
[18–20]. In immunocompromised patients such as those
with human immunodeﬁciency virus (HIV) infection, HL
usually presents as extranodal disease and B symptoms
(night sweats, fever, and weight loss), advanced stage,
commonly with bone marrow involvement [21].
HL is one of the most common non-AIDS deﬁning
neoplasms in the HIV+ population and is increasing in
prevalence in patients treated with Highly Active Anti-
retroviral Therapy (HAART) whereas the incidence of non-
Hodgkin’s lymphoma has fallen in such patients [22–25].
Older patients above the age of 60 often present with
subdiaphragmatic disease, mixed cellularity histology, and B
symptoms [17, 26].
Rarely, HL may present with paraneoplastic syndromes,
including central nervous system, renal, and other manifes-
tations [17]. Historically emphasized paraneoplastic symp-
toms include pruritus and alcohol-induced pain. Pruritus
can occur in up to 30% of patients with HL but is not
a speciﬁc ﬁnding as it can occur in patients with NHL,
leukemia, iron deﬁciency, cutaneous T cell lymphomas, and
other malignancies [27–32]. It can be severe and intractable
[27, 30, 33, 34].
Alcohol-induced pain has been associated with HL since
the early 1950s [35–47] but can occur in other conditions
such as tuberculous lymphadenitis [48]. Deliberate testing
with alcohol was reported to induce pain in 17% of patients
with HL [40]. The pain may occur immediately after drink-
ing an alcoholic beverage (the type of alcoholic beverage
does not seem to be a factor), or several minutes to hours
later, usually, but not always, in involved lymph nodes with
radiated pain distribution [40]. It can be severe enough to
“ reducethepatienttotears ”[40].Thissymptomisassociated
withearlystage,youngerpatients,thenumberofeosinophils,
and degree of ﬁbrosis in aﬀected nodes and inversely related
to the mitotic count in RS cells [40]. Interestingly, one
of the enzymes (aldehyde dehydrogenase) in the alcohol
metabolism pathway is implicated in poor outcome in HL
patients who have a macrophage gene signature in the
tumor microenvironment [49]. Since this enzyme converts
acetaldehyde,aproductofalcoholdehydrogenase,intoacetic
acid, it is possible that alcohol-induced pain is due to
acetic acid production in the tissues aﬀe c t e db yH Lh e a v i l y
inﬁltrated by macrophages. Acetic acid is commonly used
to induce acute visceral pain in mice, a test known as the
“acetic acid writhing test”, which, although conjuring images
of medieval torture, is used to this day in conscious animals
for the evaluation of pain control by analgesics [50].
4.Diagnosis
In this section, a brief discussion of the diagnostic approach,
pitfalls of cytology, and interobserver variability in histologic
assessment are highlighted. The changing deﬁnitions and
clinical characteristics of grey-zone lymphomas are dis-
cussed. Innovations in ﬂow cytometric evaluation of HL may
allow better and more rapid diagnosis of HL in the future.
The British Columbia Cancer Agency Cancer Man-
agement Guidelines (http://www.bccancer.bc.ca/HPI/Cancer
ManagementGuidelines/Lymphoma/HodgkinsDisease.htm)
recommend that the diagnosis be established by open4 Advances in Hematology
biopsy and not on the basis of ﬁne-needle aspiration biopsy.
Hodgkin’s lymphoma diagnosis and classiﬁcation is based
on appropriate cellular and tissue architectural ﬁndings.
Diagnosismaybecompromisedifthebiopsyisinsuﬃcientin
sizeorcrushed[17].Ifthereismorethanoneenlargedlymph
node, biopsy of the largest node may be more informative as
smaller nodes may only show reactive changes [51].
4.1. Role of Fine-Needle Aspiration Cytology. There are
numerousreportsontheuseofﬁne-needleaspiration (FNA)
cytology for the diagnosis of HL [52–73]. Most of these
are based on small retrospective series of cases and may
suﬀer from selection bias. FNA diagnosis of HL lesions may
be associated with a false negative rate of 15–40% [52, 66,
69]. Generally, because of diagnostic errors that may occur
even with the best histologic preparations, FNA samples
are not considered reliable enough for the diagnosis and
classiﬁcation of HL. However, this may change as a result of
the development of innovative protocols that can identify RS
cells by ﬂow cytometry using a 9-color single tube assay.
4.2. Diagnostic Pitfalls and Interobserver Variability. There
have been a few publications over the years that have
dealt with diagnostic errors in pathologic classiﬁcation of
Hodgkin’s lymphoma [74–77]. Woodruﬀ reported that 13%
of HL cases on review were reclassiﬁed as NHL and that
31% of HL cases had been incorrectly subclassiﬁed [74].
Miller et al. found that 36 of 287 (13%) cases of HL
were actually cases of NHL. Most of the cases erroneously
diagnosed as HL were diﬀuse large cell lymphomas and
often extranodal in location [75]. In a recent population-
based cancer registry study published, the diagnosis of HL
was noted to be incorrect in only 3% of cases reviewed and
concluded that cancer registries should not worry too much
aboutdiagnosticdiscrepancies[76].Thisstudy,however,was
restricted to female patients in a limited region (Greater Bay
area of Northern California) where one would expect that
the expertise of regional pathologists might be higher than
average in other parts of the world since they had ready
and continuous access to R. F. Dorfman, a world-renowned
lymphoma pathologist, and a coauthor of that study. Even
amongst expert panel members, interobserver variation in
theclassiﬁcationofHLcanbeashighas8%[78,79].Inother
studies higher error rates were noted when expert reviews
were performed [80, 81]. It would appear, therefore, that in
countries which do not mandate central review by expert
pathologists, the incidence, prevalence, histologic subtypes,
and mortality statistics of HL may need correction. Such a
central review would uncover cases of grey-zone lymphoma
(GZL) as well in a reliable manner.
4.3. Grey-Zone Lymphomas (GZLs). In the latest WHO
classiﬁcation system, a provisional category of B cell
neoplasia with features intermediate between diﬀuse large
B cell lymphoma (DLBCL) and cHL was established [9].
GZL seems to be clinically diﬀerent from standard HL
and DLBCL in presentation and response to therapy,
although the number of cases reported is quite small so
far. Dunleavy et al. presented 14 patients with GZL treated
on studies of dose-adjusted infusional etoposide/vincristine/
doxorubicin/bolus cyclophosphamide/prednisone plus rit-
uximab (DA-EPO-CH-R) [82]. The median age was 30
(range 12–51) years. Seventy one percent were of the male
gender, 14% presented with stage III/IV disease (14%), and
half the patients had elevated LDH. They described three
grey-zone groups, including overlapping features of cHL and
primary mediastinal B-cell lymphoma (PMBL) in 9 (64%)
patients,cHLandDLBCLin2patients(14%),andLPHLand
T-cell histiocyte-rich large B cell lymphoma (THRLBCL)
in 2 patients (14%). Immunohistochemistry showed the
absence of CD10 in almost all cases (only 1 of 14 cases was
positive). CD15 was positive in 33–50% and CD30 in 66–
100% of cases in the 3 groups. Reed-Sternberg-like cells were
seen in GZL with cHL features. Thirteen newly diagnosed
GZL patients, as deﬁned previously, received DA-EPOCH-R.
Of 11 evaluable patients, 10 (91%) achieved complete
response and 1 partial response. At a median follow-up time
of 4 years, overall survival and progression-free survival
were 86% and 57%, respectively. Of the 9 patients with
GZL of the cHL and PMBL overlap type, 4 (44%) also
required radiation therapy, a higher percent compared to
patients with pure PMBL (3/31; 10%) to achieve durable
remissions. They concluded that GZL represents a biological
and clinical continuum between HL and B-cell lymphomas
and that GZLs are more resistant to treatment than either
standard HL or DLBCL and may require more aggressive
management including radiation therapy.
PMBL and HL of NS subtype are now considered related
diseases and not included in the current category of GZL
[9, 83–89]. It should be also noted that overlap between
LPHL and THRLBCL is no longer included as GZL [9], as
there is evidence to suggest that the two are also related
[90–93]. Lim et al. [91] concluded that THRLBCL is of
germinal center B cell derivation in the majority of cases.
The lack of t(14;18) and CD10 expression in these cases
does not support the notion of histologic progression from
a preexisting follicle center cell lymphoma. They found
similarities to NLPHL in almost 50% of THRLBCL, but
more than half of the cases lacked LP-type neoplastic cells
(formerly termed lymphocytic and histiocytic or L & H cells,
but now called LP cells) and, instead, contain cells similar
to centroblasts or HRS cells, particularly in cases associated
with EBV.
4.4. Role of Flow Cytometry (FC). In most clinical labora-
tories, FC is not routinely used for the diagnosis of HL.
This is because RS cells usually make up less than 1%
of the lymphoid cells in HL and the microenvironment
consists of large numbers of non-neoplastic reactive T and
B cells and other cell types. Gating strategies and antibody
panels are usually designed for the identiﬁcation of NHL
in tissue biopsies. Fromm et al., however, have reported
on the utility of FC in cHL using a 9-color single tube
FC assay and successfully sorted RS cells from clinical
samples [94, 95]. FC diagnostic sensitivity and speciﬁcity
were 88.7% and 100%, respectively, when compared to
histology [94]. The cases (n = 6/53) that were not identiﬁed
as cHL by FC were due to interpreter error (1 case),Advances in Hematology 5
sampling error (no RS cells; 2 cases), delayed analysis >72
hours likely leading to loss of RS cells (2 cases), and grey-
zone lymphoma ultimately classiﬁed on morphology and
immunohistochemistry as cHL (1 case). NLPHL is not
identiﬁable by this method [94]. If this can be reproduced by
otherlaboratories,itisconceivablethatcHLcouldbereliably
diagnosedinFNAsamplesinthefuturewhencombinedwith
the 9-color assay described by Fromm et al. [94].
5. Pathobiology of HL
5.1. Cell of Origin. The neoplastic cells of cHL (Hodgkin/
Reed-Sternberg cells or H/RS cells) are almost always derived
from germinal centre B cells, with rare cases being of T cell
origin, while LP HLs (LP cells) are always of germinal centre
Bc e l lo r i g i n[ 96–104].
Although cHL H/RS cells are derived from germinal
centre B cells, they usually lose their B cell programming
[105] through a variety of mechanisms including promoter
DNA methylation [106–108] and upregulation of NOTCH1,
a negative regulator of the B cell program [109], whereas
non-B cell lineage proteins are upregulated [110]. B cell
programming cannot be reconstituted by demethylation of
cultured RS cells [111]. The biology of RS cells in cHL has
been extensively reviewed recently and thus not discussed in
g r e a td e t a i li nt h i sr e v i e w[ 100, 102, 112].
The LP cell in NLPHL is derived from antigen-activated
g e rm i n a lc e n tr eBc e ll s[ 113]. Like germinal centre B cells, LP
cells express functional IgV genes with intraclonal diversiﬁ-
cation [112], BCL6 protein [114], and GCET1 (centerin), a
germinal centre B cell-associated serpin [115]. In contrast to
H/RScells,LPcellsgenerallyretaintheirBcellprogramming.
However, selective loss of the B cell phenotype may also
occur in LP cells, including downregulation of CD19, CD37,
PAG, and LCK [116–118]. The mechanism is not related
to promoter methylation of the encoding genes [118].
Chromosomal breakpoints in IgH and BCL6 associated with
a t(3;14)(q27;q32) have been detected in 36% of LP HL
[119]. Additional BCL6 rearrangements are frequent in LP
HL, associated with t(3;22)(q27;q11), t(3;7)(q27;p12), and
t(3;9)(q27;p13) [120].
5.2. Role of EBV. The Epstein-Barr virus was ﬁrst identiﬁed
by electron microscopy of cultured lymphoblasts from
Burkitt’s lymphoma in 1964 by Epstein et al. [121]a n dw a s
identiﬁed as the etiologic agent in infectious mononucleosis
in 1968 [122, 123].
Weiss et al. showed that 19% of cHL contained the
Epstein-Barr (EBV) genome and the infected cells are
monoclonal. In situ hybridization conﬁrmed the presence
of EBV nucleic acid sequences in RS cells and their variants
[124].Subsequently,severalpapersconﬁrmedtheseﬁndings,
including the expression of LMP1 by RS cells [125–139]. Up
to 40–60% of cHL cases may contain the EBV genome [140].
ThefactthatEBVisubiquitousworldwide,infecting90%
of the adult population [141], and is B lymphocytotropic has
made it complicated in precisely determining its causative
role in HL as it may be a passenger, but not a driver in HL,
considering that up to 40%–60% of HL cases do not contain
theEBVgenome[140].EBV-associatedHDismorecommon
in Hispanics versus whites, mixed cellularity versus nodular
sclerosis histologic subtypes, children from economically
less-developed versus more-developed regions, and young
adult males versus females [142].
It is possible that two forms of HL exist, one in immu-
nologically competent patients without association with
EBV, and the other in patients with severe or subtle immune
dysfunction, where HL is associated with EBV. Even in
EBV+ HL, age-related diﬀerences in outcome have been
described, suggesting that an intact immune system may be
beneﬁcial to patients with EBV+ HL. For instance, in young
patients(<50yearsofage),completeresponsetotherapyand
2-year failure-free survival is signiﬁcantly better in EBV+ HL
cases [143, 144], while in elderly patients, EBV+ cases have a
worse outcome [145].
Familial HL is associated with EBV positivity and
HLA class I haplotype identity [146]. HLA class I region
microsatellite markers D6S265 and D6S510 are associated
with EBV+ HL while in all HLs including EBV− HL, class
III D6S273 marker shows an association [147]. Adverse
outcome in EBV− cases is associated with loss of major-
histocompatibility-complex (MHC) Class I and class II HLA
antigen expression [148]. This suggests that in EBV+ cases,
not only is an intact immune system beneﬁcial to patients
but also HLA class I polymorphism may inﬂuence the persis-
tence of EBV genome, presumably causing variable antigen
presentation during the active phase of EBV infection,
thus allowing latently infected B cells to survive the initial
immune response. EBV− HL cells may survive the immune
response by downregulating both class I and class II HLA
antigens. HLA-A∗02 can present EBV-associated peptides,
triggering eﬀective immune responses, and has been shown
to have a protective eﬀect (i.e., reduced risk of developing
EBV+ HL) [149].
TheinteractionbetweenEBV+HLcellsandthemicroen-
vironment is better understood in the context of EBV biol-
ogy. EBV gains entry into B cells using the major envelope
glycoprotein gp350 which binds to the C3d complement
receptor CD21 expressed by B cells [150]. The MHC class
II antigen acts as a cofactor for EBV infection of B cells
[151]. The binding of viral glycoprotein gp350 to CD21
occurs on the cell surface at which time it is 50nm from
the cell membrane [152]. Internalization involves a complex
of three glycoproteins, gH, gL, and gp42. Glycoprotein gp42
binds to HLA-DR [151]. EBV’s linear DNA molecule then
becomescircular,forminganepisome,andpersistsasalatent
infection in memory B cells for years [153, 154].
Whereas 94 viral proteins are encoded by the EBV
genome and are expressed during viral replication, most are
downregulated when the virus assumes its latent form, so
that only 10 continue to be expressed in latent infections
[155]. In so doing, the latently infected B cells are less
likely to be cleared by the immune response which during
the primary infection includes natural killer (NK) cells and
cytotoxic T cells [156].
The virus deploys additional strategies to escapeimmune
attack, expressing proteins that mimic various receptors and
cytokines. For instance, the BCRF1 gene encodes viral IL-106 Advances in Hematology
(vIL-10), which is highly homologous to human IL-10 and
is necessary for B cell transformation by EBV [157]. IL-10
has several properties that promote cell survival, including
upregulation of Bcl-2 [158] and inhibition of cytokine
production by macrophages and Th1 cells [159, 160]. Cer-
tain single nucleotides polymorphisms in the IL-10 gene
are associated with worse outcome [161]. This is further
discussed in another section hereinafter.
EBV latent membrane protein LMP1 mimics the CD40
receptor [162] while LMP2a mimics a B cell receptor
[163]. For detailed reviews of EBV biology see Cohen [141]
and Klein et al. [164]. Comprehensive EBV-human protein
interaction maps have been generated by Calderwood et al.
[165]. Forty three interactions between EBV proteins and
173 interactions between EBV and human proteins were
identiﬁed [165], indicating the complexity of interaction
between EBV proteins and human proteins, each interaction
with possible biologic impact.
5.3. Gene Copy Number Variation in HRS Cells. Sub-
megabase resolution tiling (SMRT) array-based comparative
genomic hybridization proﬁling revealed gains and losses
of 9 novel regions not previously reported in the litera-
ture in Hodgkin Lymphoma cell lines L428 and KMH2,
which shared gains in chromosome cytobands 2q23.1-q24.2,
7q32.2-q36.3, 9p21.3-p13.3, and 12q13.13-q14.1 and losses
in 13q12.13-q12.3 and 18q21.32-q23 [166]. Genes mapping
to these regions include cell cycle-associated genes CDK6,
PCNA, and ATM, MAPK signaling pathway genes DDIT3,
HSPB1, and MYC, genes encoding tight junction proteins
CLDN4 (claudin4) and PARD6G, Jak/Stat signaling pathway
genes STAT1, JAK2, and MYC, and ING tumour suppressor
gene ING3 [166].
Two recent studies looked at gene copy number variation
in microdissected HRS cells from clinical samples. Hartman
et al. obtained DNA from cHL cases rich in Hodgkin-
Reed-Sternberg cells to avoid ampliﬁcation-associated bias.
The cases were either LDHL or NSHL grade II. DNA
obtained from about 100,000 microdissected Hodgkin-
Reed-Sternberg cells of each of 10 classical Hodgkin’s
lymphoma cases was hybridized onto commercial (Agilent)
105 K oligonucleotide comparative genomic hybridization
microarrays. Gains were identiﬁed in at least 50% (5/10
cases) of the cases involving 2p12-16, 5q15-23, 6p22, 8q13,
8q24, 9p21-24, 9q34, 12q13-14, 17q12, 19p13, 19q13, and
20q11. Losses which were recurrent in at least 50% (5/10)
of cases were noted aﬀecting Xp21, 6q23-24, and 13q22.
Regions of gains include genes such as STAT6 (12q13),
NOTCH1(9q34),andJUNB(19p13)whichareconstitutively
expressed in cHL [167].
The second, more recent, study by Steidl et al. looked
at 53 patients, including 23 patients that had failed pri-
mary treatment [168]. In this study, fewer RS cells were
microdissected from each case (500–1000 cells per case).
DNA was extracted and subjected to whole genome ampliﬁ-
cation (WGA). Array CGH was performed on sub-megabase
resolution tiling (SMRT) arrays at a functional resolution of
50kb. Regions of gain were observed in more than 20% of
the cases in 2p, 9p, 12p, 16p, 17p, 17q, 19p, 19q, 20q, and
21q, whereas losses were noted in 1p, 6q, 7q, 8p, 11q, and
13q. Gains of 16p11.2-13.3 were associated with treatment
failure and shorter disease-speciﬁc survival. One of the genes
mapping to this region is the multidrug resistance gene
ABCC1 (encoding multidrug resistance protein MRP1, a
member of the superfamily of ATP-binding cassette (ABC)
transporters) [169, 170]. In doxorubicin-resistant HL cell
line KMH2, Steidl et al. found gains and overexpression
of ABCC1 and siRNA knock-down sensitized KMH2 cells
to doxorubicin toxicity in vitro [168]. This suggests that
primary treatment failure in cHL may be due to ampliﬁca-
tion and overexpression of ABCC1. Conﬁrmation with anti-
MRP1 monoclonal antibody immunostaining of primary
refractory and treatment sensitive cHL cases might be useful
so that this could be used to predict response in cHL by
standard immunohistochemistry (IHC).
5.4. Gene Expression Studies. In a small number of cases
(21) of cHL, using cDNA arrays covering about 1000
genes, Devilard et al. found a signature that can distinguish
between good outcome Hodgkin’s disease (GOHD) and
bad outcome (BOHD) cases [171]. They did not isolate
HRS cells by microdissection but used whole cells including
the microenvironment. GOHD cases were associated with
overexpression of genes involved in apoptotic induction and
cell signaling pathways, including cytokines, whereas BOHD
was associated with overexpression of genes associated
with ﬁbroblast activation, angiogenesis, extracellular matrix
remodeling, cell proliferation, and the downregulation of
tumor suppressor genes.
In another study including 29 cases of cHL and over
9000 genes (OncoChip.v2 cDNA microarrays), S´ anchez-
Aguilera et al. identiﬁed 145 genes predictive of outcome
[49]. Four diﬀerent signatures were obtained by supervised
hierarchical clustering, 2 of which were associated with the
host immune response of tumor microenvironment and the
other 2 with the HRS cells based on known expression in HL
cell lines and normal germinal centre B cells.
The immune response signature associated with poor
outcome was overexpression of genes expressed by speciﬁc
subpopulations of T cells such as CD8B1 (encoding the CD8
beta chain of cytotoxic T cells, a coreceptor for class I MHC
recognition), CD3D (encoding the delta subunit of the T
cell receptor/CD3 complex), CD26 (encoding dipeptidyl-
peptidase 4, also known as adenosine deaminase complexing
protein-2, or T-cell activation antigen CD26, an intrinsic
membraneglycoproteinandaserineexopeptidase),SH2D1A
(SH2 domain-containing protein 1A, also known as T cell
signal transduction molecule SAP, involved in modifying
signal transduction pathways in T, B, and NK cells),
m a c r o p h a g e ss u c ha sALDH1A1 (aldehyde dehydrogenase 1
family member A1, an enzyme that is involved in the second
step in the alcohol metabolism pathway which converts
acetaldehyde to acetic acid), LYZ (encodes lysozyme), STAT1
(encodes signal transducer and activator of transcription 1),
and CD8+ cells such as ITM2A (integral membrane protein
2A) which is induced during T cell activation and causes
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A signature associated with favorable outcome included
overexpression of genes relevant to adhesion molecules
and remodeling of the extracellular matrix such as TIMP4
(tissue inhibitor of metalloproteinase 4), SPON1 (spondin
1, extracellular matrix protein, which has vascular SMC
growth promoting activity [173, 174]), LAMB1 (laminin,
beta 1; tissue factor (TF) is constitutively associated with
laminin-binding beta(1) integrins that support TF-VIIa-
PAR2signalingleadingtoupregulationofproangiogenicand
immune modulatory cytokines and growth factors [175]),
genes active in ﬁbroblast function and chemotaxis such
as TACR1 (tachykinin receptor 1) and CCL26 (chemokine
(C-C motif) ligand 26; also known as eotaxin-3, one
of the chemokines that attract eosinophils into tissues
[176, 177]), and molecules expressed by antigen-presenting
cells such as CR1 (complement component (3b/4b) recep-
tor 1; CD35, expressed on follicular dendritic cells and
HRS cells [178]), HLA-DRB3, and subpopulations of B
cells such as IRTA2 (immunoglobulin superfamily recep-
tor translocation-associated protein 2; CD307; an EBNA2-
induced Fc-receptor homologue [179]) and VDR (VDR
agonistscanactivateCD4(+)CD25(+)regulatoryTcellsand
promote their recruitment to inﬂammatory sites [180]) [49].
Clusters 3 and 4 consisted of genes overexpressed in the
unfavorable outcome group and included genes involved in
apoptosis regulation such as CYCS (cytochrome c, somatic)
and HSPA1L (heat shock 70kDa protein 1-like; molecular
chaperone that is involved in folding of newly synthesized
polypeptides, refolding of misfolded proteins, and translo-
cation of proteins across biological membranes and has reg-
ulatory roles in signal transduction, cell cycle, and apoptosis
[181]), signal transduction such as PDCD10 (programmed
celldeath10;co-overexpressionofPDCD10canpromotecell
proliferation and transformation through regulation of the
extracellular signal-regulated kinase (ERK) pathway [182])
and PRKACB (protein kinase, cAMP-dependent, catalytic,
beta), and metabolism and cell growth such as COX7A2
(cytochrome c oxidase subunit VIIa polypeptide 2),M Y C N
(N-myc), and DCK (deoxycytidine kinase), and genes coding
for cell-cycle-regulatory proteins such as those involved in
the mitotic checkpoint such as MAD2L1 (MAD2 mitotic
arrest deﬁcient-like 1), BUB1 (budding uninhibited by
benzimidazoles 1 homolog; essential for spindle-assembly
checkpoint signaling [183]), STK6 (aurora kinase A), CDC2
(cyclin-dependent kinase 2), and CHEK1 (CHK1 checkpoint
homolog). Some of the genes encode enzymes conferring
drug resistance such as RRM2 (ribonucleotide reductase
M2; inhibits Wnt signaling [184]), TOP2A, and TYMS
(thymidylate synthetase) [49].
In a larger study, Chetaille et al. studied 63 cHL cases
(not enriched for HRS by microdissection, thus including
cells from the microenvironment) using full transcriptome
coverage (Aﬀymetrix U133 A2.0 human oligonucleotide
microarrays) and found 47 genes associated with adverse
outcome, and 403 genes associated with favorable outcome
[185]. Favorable outcome was associated with expressed
genes of the “B-cell” cluster, such as BCL11A (encoding
B-cell CLL/lymphoma 11A, a zinc ﬁnger protein), BANK1
(B-cell scaﬀold protein with ankyrin repeats), STAP1
(signal transducing adaptor family member 1), BLNK
(B-cell linker), FCER2 (CD23; low aﬃnity II receptor for
the Fc fragment of IgE), CD24,a n dCCL21 (chemokine
(C-C motif) ligand 21; chemotactic for T cells), genes
of an “apoptosis” cluster such as YWHAB (tyrosine
3-monooxygenase/tryptophan 5-monooxygenase activation
protein, beta polypeptide), CASP8, PTPRC (protein tyrosine
phosphatase, receptor type, C), and TANK (TRAF family
member-associated NFKB activator), and genes of the “cell
metabolism” cluster. Genes associated with unfavorable
outcome were in the “extracellular matrix” cluster such
as collagen genes COL1A1/4A1/4A2/5A1/18A1, THBS1/2
(thrombospondin 1and 2), FN1 (ﬁbronectin 1), EDNRA
(endothelin receptor type A), ITGB5 (integrin, beta 5), and
LAMA4 (laminin, alpha 4) [185].
GlobalgeneexpressionanalysisofmicrodissectedLPcells
(L & H cells) from 5 cases of NLPHL has been reported
by Brune et al. [186]. The gene expression signatures when
examined by principal component analysis (PCA) were
closer to T cell-rich B cell lymphoma and classical HL than
to diﬀuse large B cell lymphoma, Burkitt lymphoma, and
follicular lymphoma. Forty three genes were diﬀerentially
expressed in LP cells (using false discovery rate (FDR)
ﬁlter set at <0.05 after applying the t test) in comparison
with cHL HRS cells, whereas 295 genes were diﬀerentially
expressed in comparison with FL cells. By relaxing the
FDR ﬁlter to <0.1, a total of 129 genes were found to
be diﬀerentially expressed between LP cells and HRS cells,
123 of which had higher expression in LP cells, and 6
were higher in expression in HRS cells. Of interest is the
increased expression of ABCC1 in LP cells, which, as already
discussed, encodes multidrug resistance protein MRP1 [169]
andisalsoampliﬁedandoverexpressedinprimarytreatment
refractory cHL [168]. Two other genes of practical relevance
includeCTSB(cathepsinB)andLGALS3 (lectin,galactoside-
binding, soluble), the encoded proteins of which label LP
cells in 100% of NLPHL cases [186].
5.5. Host Microenvironment/Immune Response. The micro-
environment in LP HL is diﬀerent from that in cHL. An
interesting phenomenon has been reported in LP HL, in
which a population of CD4+CD8+ CD1a− TdT− (double
positive or DP) T cells is detected, comprising up to 38% of
T cells in 58% of LP HL cases. Such cells are also found in
38% of cases of progressively transformed germinal centers
(PTGCs) but are relatively infrequent (6%) in cHL. Similar
DP T cells have been found in melanomas and in breast
cancer tissue and pleural eﬀusions associated with breast
cancer [187, 188]. They produce TNF-alpha, IL-13, IL-4,
and IL-5 at higher levels than conventional mature T cells
[187]. Such cells are seen in various other species and are
considered to be class II restricted memory CD4+ helper
T cells that acquire CD8 alpha chain after activation [189].
Age-dependent increases in DP T cell have been reported in
e l d e r l yh e a l t h ys u b j e c t s[ 190].
Although most patients with cHL are cured with
ﬁrst-line therapy, 15%–20% of patients with stage I–II
HL and 35%–40% of patients with stage III–IV HL and
adverse risk factors relapse after ﬁrst-line therapy [191, 192].8 Advances in Hematology
Patients with relapsed or refractory HL often receive
second line, salvage chemotherapy followed by high-dose
chemotherapy and autologous stem cell transplant
(HDCT/ASCT). Patients who fail HDCT/ASCT have a
poor outcome [192–195]. A recent observation of host-
response gene signatures highlighted the tumor-associated
macrophage gene signature as signiﬁcantly associated with
primary treatment failure. The increased number of CD68+
macrophages identiﬁed by IHC was associated with a
shortened progression-free survival, an increased risk of
relapse after HDCT/ASCT, and shortened disease-speciﬁc
survival.Inmultivariateanalysis,CD68+cellsasaprognostic
factor were superior to the International Prognostic Score
for disease-speciﬁc survival. The absence of an increased
number of CD68+ cells in patients with limited-stage disease
predicted long-term disease-speciﬁc survival of 100% in
cHL patients treated with current treatment protocols [196].
Thus a relatively simply performed IHC assay for CD68,
which is widely available in clinical laboratories, can identify
patients with HL who are likely to be refractory to ﬁrst
line therapy and is thus the ﬁrst predictive in vitro test for
cHL [197]. This also raises the possibility that modulating
macrophage numbers and/or function with anti-CD68 or
other macrophage-speciﬁc monoclonal antibodies might be
a therapeutic strategy worth exploring.
5.6. MicroRNAs. MicroRNAs are short, noncoding RNAs
that are part of RNA silencing pathways that function
either by targeting messenger RNAs for degradation or
by repressing translation [198]. The BIC (B-cell receptor
inducible) transcript which contains microRNA-155 (miR-
155) is expressed in cHL, activated B cell-like diﬀuse large B
cell lymphoma, and primary mediastinal B cell lymphoma
(PMBL) [199]. It has been shown that miR-155 expression
is higher in EBV-immortalized B cells than in EBV-negative
B cells. LMP1, but not LMP2, upregulates the expression
of miR-155 [200]. AGTR1 (angiotensin II receptor, type 1),
FGF7 (ﬁbroblast growth factor 7), ZNF537 (TSHZ3; teashirt
zinc ﬁnger homeobox 3), ZIC3 (Zic family member 3), and
IKBKE (inhibitor of kappa light polypeptide gene enhancer
in B-cells, kinase epsilon) are miR-155 target genes in cHL
[201].
The expression proﬁling of miRNAs in cHL and reactive
nodes revealed 3 groups: nodular sclerosis cHL, mixed
cellularity cHL, and reactive lymph nodes (RLNs). Twenty
ﬁve miRNAs diﬀerentiated cHL from RLNs, and 36 miRNAs
were diﬀerentially expressed in the nodular sclerosis and
mixed cellularity subtypes. MiR-96, miR-128a, and miR-
128b were selectively downregulated in cHL containing the
EBV genome [202].
PRDM1/blimp-1 (PR domain containing 1, with ZNF
domain; Beta-interferon gene positive regulatory domain
I-binding factor) is a transcriptional repressor that binds
speciﬁcally to the PRDI element in the promoter of the beta-
interferon gene and drives the maturation of B-lymphocytes
into immunoglobulin secreting cells. It is a target for
downregulation by miR-9 and let-7a in HRS cells of cHL.
MiRNA-mediated downregulation of PRDM1/Blimp-1 may
contribute to the loss of the B cell program in HRS cells by
interfering with normal B-cell terminal diﬀerentiation [203].
Patients with cHL demonstrating low miR-135a expres-
sion have a higher probability of relapse and a shorter
disease-free survival. Downregulation by miR-135a of JAK2,
a cytoplasmic tyrosine kinase involved in cytokine receptor
signaling pathways, causes decreased mRNA and protein
levels of the antiapoptotic gene Bcl-xL, supporting a possible
role for Bcl-xL in miR-135a/JAK2-mediated apoptosis [204].
Microdissected HRS cells, when compared to CD77+
germinal centre B cells, assessed for a panel of 360 miRNAs,
showupregulationof12miRNAsincluding miR-155(targets
AGTR1, SOCS1, CD47, NAMPT, IKBKE, BCL11A), miR-
21 (targets PTEN, BCL11A, BCL2, CD47), miR-20a (targets
TGFBR2, SMAD5, SOCS6), miR-9 (targets BCL11A, BCL6,
NFKB1, CD47, SOCS5), and miR-16 (targets BCL2, CD164,
SOCS6) and downregulation of 3 miRNAs miR-614 (targets
FOXD1), miR-200a# (targets ZEB1, ZEB2, STAT4, STAT5A,
STAT5B, JUN), and miR-520a# (targets BCL6, BTG1, PBX3,
BCL11A, BCL11B)[ 205]. These are interesting observations,
since several targets of upregulated miRNAs are themselves
regulators of lymphocyte function. For instance, SOCS1,
SOCS5, and SOCS6 are members of the suppressors of
cytokine signaling family [206], and thus silencing by miR-
NAsshouldleadtoincreasedcytokinesignalingandresponse
due to reduction in suppression of cytokine signaling. PTEN
silencing may lead to unopposed phosphoinositide 3-kinase
(PI3K) activity which may contribute to the development of
lymphomas [207].
5.7.SingleNucleotidePolymorphisms (SNPs)inSelected Genes
in HL. Nieters et al. have looked at SNPs in genes encoding
the family of Toll-like receptors (TLRs), IL10 and IL10RA in
710 patients with various forms of lymphoma, and matched
controls and found that the IL10RA Ser138Gly variant had
a 50% protective eﬀect against Hodgkin’s lymphoma (HL)
[208]. Hohaus et al. looked at IL10 plasma levels and SNPs in
the IL10 gene promoter in patients with HL and found that
patients with high IL-10 levels were tended to have advanced
stage and worse outcome. Variant alleles at position-592
(AA) and -1082 (GG) of the IL-10 promoter were associated
with increased IL-10 plasma levels [209]. In an earlier study,
Hohaus et al. had found by multivariate analysis that the IL-
10-592AA and the IL-6-174GG genotypes were independent
prognostic factors in HL patients [161].
Chang et al. have reported that regular use of aspirin
reduces the risk of developing HL [210], and since aspirin
inhibits the activation of the transcription factor nuclear
factor-κB(NF -κB)viainhibitionofIκBkinaseβ,anacti vat or
of NF-κB[ 211], they investigated whether SNPs in genes
involved in nuclear factor-κB( N F - κB) activation and inhibi-
tion, other inﬂammatory pathways, and aspirin metabolism
inﬂuence HL risk in 473 patients with cHL and 373 controls
[212]. They found that HL risk was signiﬁcantly associated
with refSNP ID rs1585215 in NFKB1 (AG versus AA and GG
versus AA) but could not ﬁnd an association with aspirin
use or with SNPs in aspirin-modulated genes IKKA/CHUK,
PTGS2/COX2, CYP2C9, UGT1A6,o rLTC4S [212]. In a
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HL, they found a protective eﬀect of low-dose aspirin, but
not other nonsteroidal anti-inﬂammatory drugs NSAIDs,
against Hodgkin lymphoma development [213].
Polymorphisms in 3 nucleotide excision repair path-
way genes (XPD [Lys751Gln], XPC [Lys939Gln], and XPG
[Asp1104His]), the base excision repair XRCC1 (Arg399-
Gln), and double-strand break repair XRCC3 (Thr241Met)
were studied in 200 HL patients and 220 matched con-
trols. A positive association was found between combined
XRCC1/XRCC3 and XRCC1/XPC polymorphisms and risk
of HL [214].
5.8. Mechanisms of Chemoresistance. As previously dis-
cussed,bothLPandHRScellsinclinicalsamplesoverexpress
the multidrug resistance gene ABCC1, and HRS cells contain
increased copy number of the ABCC1gene[168,186].Shafer
et al. have shown that primary HL tumor samples contain
a population of cells (0.2% to 6.5%) with the ability to
increase eﬄux of Hoechst 33342 dye and are resistant to
gemcitabine, a commonly used drug for the treatment of
refractory HL. These cells not only have the phenotype of
HRScellsbutalsoexpress multidrug resistancegenes ABCG2
and MDR1 (ABCB1)[ 215]. Thus HRS cells may be using
u pt o3d i ﬀerent multidrug resistance proteins to survive the
eﬀects of chemotherapy.
Staege et al. have studied the sensitivity of HL cells
for cytotoxic drugs (cisplatin, etoposide, melphalan) and
compared the gene-expression proﬁles of chemoresistant
and sensitive cell lines. Genes upregulated in resistant
cells include those encoding cytokine receptors (IL5RA,
IL13RA1), markers expressed on antigen-presenting cells
(CD40, CD80), as well as genes with known association to
chemoresistance, such as myristoylated alanine-rich protein
kinase C substrate and PRAME (preferentially expressed
antigen in melanoma) [216].
Kashkar et al. have reported that chemoresistance in
HL is related to XIAP (X-linked inhibitor of apoptosis) as
an NF-kappaB-independent target of bortezomib. Low-dose
bortezomib sensitizes HL cells against a variety of cytotoxic
drugs without altering NF-kappaB activity [217].
6. Novel Therapies and New Targets for
DrugDevelopment
As the prognosis of HL patients who relapse after
HDCT/ASCT is poor, several novel therapies have been or
are being assessed for chemoresistant patients, including
anti-CD20 and anti-CD30 antibodies, lenalidomide, histone
deacetylase inhibitors, mammalian target of rapamycin
(mTOR) inhibitors, cytotoxic T-lymphocyte therapy, and
reduced-intensity allogeneic transplants (reviewed in [218]).
Several of these approaches are highlighted in this section.
6.1. Rituximab. Since LP cells in NLPHL express CD20,
the role of the anti-CD20 monoclonal antibody, rituximab
(Rituxan),hasbeenexploredinNLPHLinthepastfewyears,
starting with a few cases studies such as that reported by
ˇ Culi´ c et al. [219] in which a pediatric patient refractory to
ABVD plus radiation therapy achieved complete remission
following rituximab infusion. Zojer et al. reported an
adult patient with NLPHL who responded to another anti-
CD20 antibody, yttrium-90-labelled ibritumomab tiuxetan
(Zevalin) [220]. Schulz et al. have reported the results of
the German Hodgkin Study Group (GHSG) phase II trial
investigating the role of rituximab on refractory or relapsed
patients with NLPHL. The overall response rate was 94% in
15patientsconﬁrmedtohaveNLPHLaftercentralpathology
review, including a 53% complete response rate [221]. In
another trial, from Stanford University, including treatment-
naive patients as well as refractory or relapsed patients,
Ekstrand et al. found an overall response rate of 100%
and a complete response rate of 41%, but the duration
of response was short (median time to progression 10.2
months) [222]. NLPHL successfully treated with rituximab
may be associated with relapse with CD20 negative T cell
richBcelllymphoma[223],andthusthelong-termoutcome
of rituximab-treated patients with NLPHL remains to be
determined.
Rituximab therapy has also been investigated for the
treatment of cHL. This may seem odd since HRS cells do
not generally express CD20 due to loss of the B cell program
[224–226], but the rationale is based on the hypothesis
that a B cell rich tumor microenvironment is associated
with favorable outcome [185, 196]. This does not make
sense because, if small B cells in the microenvironment
are responsible for better outcomes in HL, then destroying
them with anti-CD20 antibodies would be expected to be
detrimental to outcome. Others have argued that small B
cellsinthemicroenvironmentdeliversurvivalsignalstoHRS
cells including ligands for CD30 and CD40 and suppress
T cell-mediated immune responses by producing IL-10
(reviewed by Oki and Younes [227]) and that clonotypic
circulating B cells may be precursors to HRS cells [228].
Pilot studies have demonstrated positive initial results when
rituximabwasusedasasingleagentforrelapsedorrefractory
disease [229]. One could argue that this is conceivably due
to shrinkage of aﬀected nodes just due to elimination of
normal B cells which vastly exceed the number of HRS
cells in aﬀected nodes, and not a true response by HRS
cells. Clinical trials, however, have shown some promise.
In a phase II study of relapsed or refractory cHL the
activity of gemcitabine and rituximab was investigated in 33
patients, with objective responses in 48% of the patients,
but the median duration of failure-free survival was only
2.7 months [230]. Rituximab plus gemcitabine, ifosfamide,
and oxaliplatin (R-GIFOX) has been reported as a less
toxic, cytoreductive, and stem cell mobilizing alternative
to cisplatin-based salvage regimes, useful not only for pre-
ABMT cytoreduction but also for a full salvage treatment
program to be safely delivered to patients unﬁt for high-dose
procedures [231]. Rituxan plus ABVD is associated with an
event-free survival signiﬁcantly better than ABVD without
rituxaninbothpatients withIPSscoresof0–2andIPSscores
>2[ 232, 233]. A new GHSG trial (HD18) enrolling patients
will be evaluating individualization of treatment according
to early response to chemotherapy. Patients with IIB (with
large mediastinal mass or extranodal inﬁltration), III A/B,
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cycles of chemotherapy will receive eight cycles of escalated
BEACOPP + rituximab (BEACOPPesc + R) and will be
compared to those receiving eight cycles of chemotherapy
(BEACOPPesc) alone with the primary endpoint being
progression-free survival (PFS). For patients with PET-
negative lesions after two cycles of chemotherapy the exper-
imental arm (four cycles of BEACOPPesc) will be compared
against standard treatment (eight cycles of BEACOPPesc)
with the primary endpoint of PFS.
6.2. Anti-CD30 Monoclonal Antibodies. Av a r i e t yo fe a r l y
anti-CD30 preparations have been tried with little or at
the most modest eﬀects [218]. Toxicities are signiﬁcant,
including grade 3 to 5 pneumonitis, grade 1 to 2 fatigue,
neutropenia, peripheral neuropathy, nausea, diarrhea, and
pyrexia, febrile neutropenia, grade 3 vomiting, and grade
4 hyperglycemia, and severe hematologic toxicities (with
radioimmunoconjugates) [218]. However, currently, a num-
ber of new preparations such as SGN-30, SGN-35, and
MDX-060 have been or are being evaluated.
6.3. SGN-30. SGN-30 is a chimeric monoclonal antibody
with humanized heavy and light chain constant domains.
It initially showed activity against HL cell lines in vitro
a n di nx e n o g r a f tm o d e l s[ 234] and was also shown to be
able to sensitize HL cell lines to chemotherapeutic agents
[235]. The in vivo eﬀects of SGN-30 seem to be dependent
on Fc-receptor positive macrophages [236]. In a phase II
studyonmonotherapywithSGN-30inrefractoryorrelapsed
patients, however, objective responses were not observed in
HLpatients,althoughafewpatients(29%)hadstabledisease
(duration 62–242 days). Toxicity was common but mild or
moderate [237].
6.4. MDX-060. MDX-060 is a fully human IgG1 kappa
monoclonal antibody reactive against CD30 [238] and,
although well tolerated, has modest activity (6% response)
in patients with HL [239].
6.5. SGN-35. SGN-35 (brentuximab vedotin) is an anti-
body-drug conjugate (ADC) containing the potent tubulin
inhibitor, monomethylauristatin E (MMAE), linked to
the anti-CD30 chimeric monoclonal antibody, cAC10
[240]. MMAE is a derivative of the cytotoxic tubulin
modiﬁer auristatin E and was covalently coupled to cAC10
through a valine-citrulline peptide linker. The ADC is
stable as there is only a 2% release of MMAE following
prolonged incubation in human plasma. However, after
receptor-mediated internalization, it is cleaved by lysosomal
proteases, which leads to the release of MMAE into the
cytosol. It then induces G2/M-phase growth arrest and
cell death through the triggering of apoptosis [240]. In a
phase I trial 29 patients including 26 with heavily treated
relapsed or refractory HL were treated with increasing doses
of SGN-35. Outpatient infusions of SGN-35 were generally
well tolerated. Of the 28 evaluable patients clinical beneﬁt
(PR + SD) was observed in 20 patients (71%) [241]. In a
subsequent report, of 28 evaluable patients treated at doses
≥1.2mg/kg, 46% (n = 13) were noted to have an objective
response (CR + PR), with a CR rate of 25% (n = 7). Two
additional PRs were observed in the cohort that received
a lower dose (0.6mg/kg). Median response duration at
the time of the report was 22 weeks [242] .Ar e c e n tp r e s s
release from Seattle Genetics Inc. and the Takeda Oncology
Company indicates that in a pivotal trial of single-agent
brentuximab vedotin (SGN-35) conducted in 102 relapsed
or refractory HL patients, 75 percent of patients achieved an
objective response (not further broken down into CR, PR,
SD rates), with a median duration of response greater than
six months (http://www.news-medical.net/news/20100927/
Takeda-announces-SGN-35-ADC-trial-results-in-Hodgkin-
lymphoma-patients.aspx). Results from the pivotal trial
are expected to be presented at the 2010 ASH annual
meeting. A current trial is also evaluating the combination of
SGN-35 and ABVD (http://www.lymphomainfo.net/news/
studies-and-trials/seattle-genetics-begins-combination-trial
-of-sgn-35-plus-abvd). These trials appear to provide some
options for heavily treated HL patients who have failed
current therapies including HDCT/ASCT. A recent pub-
lication showed that MMAE is released from SGN-35
within CD30+ cancer cell lines and is able to exert cytotoxic
activity on bystander CD30− cell lines due to its ability
to cross plasma membranes [243]. This might explain the
superior clinical responses seen with SGN-35 compared to
unconjugated anti-CD30 antibodies. However, theoretically,
this might limit the dose of SGN-35 used clinically as it
is unclear whether the released MMAE can have systemic
nonspeciﬁc cell damage and resulting toxicity.
6.6. Bendamustine. Bendamustine is a mechlorethamine
derivative with a purine-like benzimidazole ring and has
structural similarities to alkylating agents and antimetabo-
lites but is non-cross-resistant with other alkylating agents
and other drugs [244, 245]. Although it regained importance
through its utility in treating rituximab resistant indolent
B cell NHL [246], recently it has been reported that
bendamustineishighlyactiveinheavilypretreatedrefractory
or relapsed HL and enables referral to nonmyeloablative
allogeneic stem cell transplant (NMT) in a signiﬁcant
number of eligible patients [247].
6.7. Revlimid. Preliminary ﬁndings have been presented
on Phase II study including 35 evaluable patients with
refractory or relapsed HL treated with single agent lenalido-
mide (Revlimid), an immunomodulatory drug. The authors
observed 1 CR, 5 PR, and 6 SD greater than 6 months.
The overall response rate was 17% and the overall cytostatic
response rate was 34%. Median duration of CR/PR was 4.5
(range 2–10) months [248]. In another report single-agent
lenalidomide was well tolerated and eﬀective in 12 patients
with refractory or multiple relapsed HL. All patients showed
disease stabilization, and 50% responded (CR + PR) to,
including one patient with complete remission even after 24
months at the time of the report. An international phase II
study of single agent lenalidomide in relapsed HL patients
is being planned, and an international phase I/II study of
lenalidomide combined with conventional chemotherapy
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6.8. HDAC Inhibitors. As noted in a previous section,
epigenetic changes are responsible for the silencing several
B lineage genes in HRS cells, likely helping these cells to
survive usual apoptotic pressures and to avoid immune-
mediated destruction [106–108, 250]. With this in mind,
several investigators have looked at the eﬀects of histone
deacetylase (HDAC) inhibition on HRS in vitro, and these
studies have led to clinical trials of HDAC inhibitors
[251–254]. A study of the expression of HDAC isoforms in
HL tissue microarrays has shown that HDAC isoforms 1,
2, and 3 are highly expressed in HL, and reduced HDAC1
expression is associated with inferior outcome in HL [255].
MGCD0103 is an oral isotype-selective inhibitor of histone
deacetylases (HDACS) with activity in preclinical models of
hematopoieticcancersandhasbeenstudiedinaphaseIItrial
in patients with relapsed/refractory classical HL, resulting in
a 45% overall response [256].
6.9. CYB5B. A recently reported 21kDa protein [257],
identiﬁed as CYB5B [258], which is normally expressed in
the outer mitochondrial membrane, is overexpressed in cHL
in the cytoplasm and plasma membrane of HRS cells but
not at the plasma membrane of normal reactive lymphocytes
or bone marrow precursor cells [258]. Array CGH using
a submegabase resolution tiling array revealed gains in the
CYB5B locus in HL cell lines KMH2 and L428 [258]. HL cell
linesshowincreasedCYB5BmRNAbutreactivelymphocytes
and bone marrow precursor cells show no increase in CYB5B
mRNA [258]. By its location at the plasma membrane only
in neoplastic cells in cHL, diﬀuse large B cell lymphoma
(DLBCL), and anaplastic large cell lymphoma (ALCL),
CYB5B might be an attractive target for antibody-based
therapy as toxicity should be minimal since normal, reactive
lymphocytesandCD34+bonemarrowprecursorcellsdonot
express the protein at the plasma membrane [258].
7. Conclusions
One hundred seventy eight years after its discovery by
Thomas Hodgkin, Hodgkin’s lymphoma continues to fasci-
nate us. Although derived from germinal centre B cells, the
neoplastic cells of HL appear to have rid themselves of the
normal B cell program and avoid what should normally lead
to triggering of programmed cell death through a seemingly
symbiotic relationship with its microenvironment which is
unlike other types of B cell lymphomas. The mechanisms
of chemosensitivity and chemoresistance are beginning to
be understood but managing patients who have primary
chemorefractory disease or relapse after the most aggressive
salvage therapies continues to be a challenge. Novel therapies
are being investigated in order to achieve superior outcomes
in chemorefractory patients.
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